If you or someone you know has ever been diagnosed with an immune-mediated chronic disease, or if you’re the parent of a child with a chronic and painful illness, then you know how important new frontiers in the medical management are of those diseases. Stratera Biopharma (STAB) is currently in the third and final IRB approved phase for their clinical trials examining the efficacy of STAT-201 in the treatment of pediatric Chrohn’s disease. Previous phases of the trial showed great promise, and all of this has investors starting to pay more attention to this stock.
STAB is a clinical-stage biopharmaceutical company developing innovative immunotherapies targeting a wide host of health issues people may face today. Specifically, these therapeutics harness (and trick) one’s own immune system into coming to the body’s defense against autoimmune diseases (diseases where the body attacks its own organ systems), inflammation, infections, and even cancer.
Crohn’s Disease (CD), is a chronic inflammatory condition of the gastrointestinal (GI) tract. This is often a painful and debilitating disease, causing symptoms ranging from unpredictable diarrhea, GI pain, and bleeding, all of which can cause significant emotional distress. Further, many of the current therapies to help manage those symptoms can often cause very uncomfortable, and sometimes even intolerable side effects, not to mention undue financial burden. In the pediatric population, Crohn’s disease is thought to be one of the most prevalent chronic conditions, and up to 30% of individuals are so diagnosed with CD before they leave their teen years. According to the Crohn’s and Colitis Foundation, CD affects approximately 1.6 million Americans. That is a lot of suffering.
Enter companies like Stratera Biopharma, which is undertaking The Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of STAT-201 in Pediatric Patients Aged 12 to 17 years with Active Crohn’s Disease. The intent is to evaluate the safety and efficacy of STAT-201 compared to placebo in establishing remission in pediatric CD patients. In the recently conducted Phase 2 portion of the study, STAT-201 induced remission in 67% of participants! Further, endoscopic studies demonstrated that 43% of participants had GI mucosal lining healing, and there were NO serious adverse effects from the treatment. This. Is. HUGE, folks….can you imagine the improvement in people’s lives if the final phase of this study yields equally as promising results?
Again, let me remind you that STAB focuses on the development of treatments not only for CD, but also for inflammation, infectious disease (i.e., COVID, which they are currently investigating), and cancer. If they can figure out ways to harness the immune system to hone in and mitigate/eradicate disease pathogens, inflammatory responses, and possibly other autoimmune diseases such a multiple sclerosis……this NASDAQ stock stands to vault right back up to it’s nearly $7 pps of approximately one year ago. We are sitting at the bottom now, watching…..but you’d be best advised to watch closely, because the POTENTIAL of this company and it’s promising therapeutics is significant. It’s huge, and there’s nothing more to say on that.
positioned to achieve numerous milestones in 2022. Following the recent submission to the FDA of our Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn’s Disease, we plan to use proceeds from our recent registered direct offering to initiate patient enrollment in the second quarter. Additionally, use of proceeds will include the enrollment of patients with acute COVID-19 infection in our STAT-205 study, from which we are targeting to have preliminary data this year.”